Infringement Analysis in Galway.

A patent infringement analysis Galway medical-device companies can rely on has to be built for two facts on the ground: Galway is one of Europe’s leading medtech clusters, and Ireland enforces patents nationally in the High Court rather than through any local division of the Unified Patent Court. The city and its ring of towns host Medtronic, Boston Scientific, Abbott and a dense ecosystem of suppliers and University of Galway spin-outs — the reason roughly 80% of the world’s coronary stents are made here. That cluster writes a distinctive infringement docket of cardiovascular devices, catheters, diagnostics and the materials and methods behind them. Because Ireland has signed but not yet ratified the UPC Agreement, a European patent asserted against a Galway defendant is decided by an Irish judge under the Patents Act 1992, not a UPC panel. PerspireIP builds the element-by-element claim charts and dated evidence-of-use that an Irish court and its case-management judge can adopt.

Where a patent infringement analysis Galway case is heard

Ireland does not spread patent disputes across the local Circuit or District courts. With limited exceptions, patent infringement and revocation actions are reserved to the High Court, and in practice they are run through the High Court sitting in Dublin — there is no separate patents court in Galway or the west. A Galway rights-holder or a Galway-based defendant therefore litigates in the national forum, even where the technology, the factory and the witnesses are all in Connacht.

Most contested patent matters do not stay on the ordinary High Court list. Either party can apply to have the case entered into the Commercial Court — the fast-track division whose entry criteria in Order 63A of the Rules of the Superior Courts expressly include proceedings under the Patents Act 1992. Since 2021 the Commercial Court has run a dedicated Intellectual Property and Technology list, which has gained particular traction in patent cases. Entry is by motion, supported by a solicitor’s certificate explaining why the dispute belongs on the list.

The Commercial List matters to how an analysis is built. It is an intensively case-managed, fast-track regime: the judge sets a tight timetable for pleadings, discovery, expert reports and trial, and expects the parties to arrive with their technical case already assembled. A patent infringement analysis Galway litigants commission has to be report-ready to that tempo, not a work in progress.

• High Court — the court of first instance for patent infringement and revocation actions under the Patents Act 1992, sitting in Dublin
• Commercial Court, IP & Technology list — the fast-track division (established 2021) that case-manages higher-value patent disputes entered under Order 63A
• Order 63A entry — by motion and solicitor’s certificate; proceedings under the Patents Act 1992 are an express qualifying category
• Court of Appeal, then the Supreme Court — the appellate route from a first-instance Irish patent judgment

Ireland, the UPC and the missing local division

This is the single most important jurisdictional point for anyone enforcing a European patent against a Galway operation. Ireland signed the Agreement on a Unified Patent Court more than a decade ago, but it has not ratified it. Ratification would transfer jurisdiction over patent litigation from the Irish courts to an international court, which under Article 29 of the Constitution requires the people to approve a constitutional amendment in a referendum.

That referendum has been repeatedly deferred. A vote pencilled in for 7 June 2024 to run alongside the European and local elections was postponed, and later hopes of pairing it with the autumn 2025 presidential poll faded when the government’s September 2025 competitiveness plan omitted UPC ratification entirely. The practical result: there is no Irish local division of the UPC, and Ireland is not a participating member state. A unitary patent has no effect here, and a classical European patent validated in Ireland is enforced nationally, in the Irish High Court, under the Patents Act 1992.

Strategically, this splits enforcement for a Galway-facing dispute. If the alleged infringing acts occur in Ireland — manufacture, sale or supply from a Galway site — the patentee sues in Dublin, and a UPC judgment obtained elsewhere in Europe will not by itself reach Irish acts. Conversely, a company sued at the UPC in Germany or at the Milan section cannot import that forum’s procedure into an Irish case. Any analysis has to be scoped to the Irish national action on its own terms, while keeping a parallel European strategy in view.

• Signed, not ratified — Ireland is a UPC signatory but not a participating state; ratification is stalled pending a constitutional referendum
• No Irish UPC division — European patents in force in Ireland are enforced nationally before the High Court, not any local or regional UPC division
• Referendum deferred — the planned 2024 vote was postponed and no firm date has replaced it, so national enforcement remains the reality
• Split strategy — Irish acts are litigated in Dublin; a UPC action abroad does not cover them, so a Galway matter needs its own Irish claim charts

Galway’s medtech cluster and the infringement questions it raises

Galway’s patent docket is written by one industry above all others. The city anchors one of Europe’s leading medical-device clusters, home to major operations of Medtronic, Boston Scientific and Abbott, alongside a deep bench of contract manufacturers, materials suppliers and University of Galway spin-outs. The sector employs on the order of 15,000 people in the Galway area, and the region has become the global centre of coronary-device manufacture: an estimated 80% of the world’s stents are produced here, together with the guidewires, hypotubes and delivery systems that go with them.

Device patents raise infringement questions that a software or chemical case never touches. Cardiovascular and structural-heart products — drug-eluting stents, balloon and delivery catheters, guidewires, heart valves and neurovascular devices — are defined by geometry, mechanics and materials as much as by function. Claims read on strut patterns and cell design, crimp and expansion behaviour, coating chemistry and drug-release kinetics, polymer and nitinol alloy composition, and the methods of manufacture that produce them. Diagnostics and combination products add assay chemistry and method-of-use claims to the mix.

• Cardiovascular and structural heart — stents, delivery and balloon catheters, guidewires, heart valves and neurovascular devices, where claims turn on geometry, mechanics and materials
• Coatings and drug-device combinations — drug-eluting coatings and release kinetics, where infringement blends materials analysis with formulation-style proof
• Materials and process — nitinol and polymer composition, laser cutting, electropolishing and other methods-of-manufacture claims proven from the article and the line
• Diagnostics — assay chemistry, sensors and method-of-use claims common across the cluster’s in-vitro and point-of-care products

These features shape the whole engagement. Proving that one stent or catheter infringes another is a laboratory and metrology exercise, and the claim chart has to be anchored to measurements a court-appointed or party expert can reproduce.

Evidence-of-use for medical-device disputes

Ireland offers discovery, so a rights-holder can compel documents from the other side, but for device cases the strongest evidence usually comes from the accused product itself. Because Galway matters turn on physical structure, materials and process, evidence-of-use is built in the laboratory before it is argued in court. A credible file combines an independent teardown of the accused device with quantitative analysis and, where relevant, the defendant’s own regulatory record.

• Device teardown and metrology — dimensioned imaging, micro-CT and microscopy of strut geometry, cell pattern, wall thickness and joint construction, tied to each claim limitation
• Materials analysis — alloy and polymer identification, coating composition and thickness, and drug-release characterisation to read on materials and coating claims
• Regulatory and technical-file evidence — the accused product’s US FDA 510(k) summary or PMA, and its EU CE / MDR technical documentation, which often describe structure and materials in the manufacturer’s own words
• Manufacturing and process proof — where a method-of-manufacture claim is asserted, evidence of laser cutting, electropolishing, crimping or coating steps drawn from discovery, published literature and the product

Regulatory filings deserve special attention. A device cleared through a 510(k) is marketed as substantially equivalent to a predicate, and the summary, the labelling and the CE technical file frequently admit the very structural and material features a claim requires. Marrying those public and disclosed admissions to independent teardown data produces evidence-of-use that is hard to dismiss as advocacy.

Building claim charts for an Irish forum

The High Court and its Commercial List judges expect a disciplined, self-contained technical case delivered to a tight timetable. We start from claim construction — claims read in light of the specification and prosecution history under Irish and European principles — then map each limitation against the real accused device, literally and, where it arises, under the doctrine of equivalents as applied in Ireland. Every mapped element is tied to a dated, documented piece of evidence a testifying expert can reproduce on the stand.

• Element-by-element claim charts linking each limitation to teardown, metrology, materials or regulatory evidence a court expert can re-run
• Medical-device evidence-of-use from imaging, materials analysis, drug-release data and the accused product’s 510(k) or CE/MDR technical file
• Non-infringement and design-around positions for an accused Galway manufacturer, anchored to the specification and file wrapper
• A coordinated invalidity file, because a revocation counterclaim routinely runs alongside an infringement action in the Irish High Court
• Deliverables paced to the Commercial Court timetable, ready for expert reports and cross-examination rather than left open-ended

Because Ireland decides these cases nationally, the deliverable is scoped to the Irish action. We keep any parallel European or UPC exposure in view, but the core product is a chart an Irish judge and an independent expert can adopt, built on measurements and disclosed records rather than conclusions.

How PerspireIP scopes a Galway infringement-analysis engagement

Every engagement follows the same path. We fix the correct claim construction, map each element against the accused device, and assemble evidence-of-use in the form the technology demands — teardown and metrology for a stent or catheter, materials and coating analysis for a drug-device product, regulatory and process evidence where a method claim is in play. Then we package the file for the way Ireland actually litigates: a national High Court action, case-managed on the Commercial List.

• Claim construction and element-by-element charting against an Irish national patent or a European patent validated and enforced in Ireland
• Evidence-of-use assembly documented for the High Court and its Commercial Court IP & Technology list, paced to the case-management timetable
• Infringement and non-infringement positions built for either side, coordinated with any parallel revocation challenge or European action
• Deliverables scoped to the track — a High Court plenary summons, a Commercial List motion, or a supporting expert file

We work alongside your Irish and international counsel as a specialist analysis partner, deliver to High Court and Commercial Court deadlines, and keep every engagement confidential. Whether you are a Galway medtech company enforcing a device portfolio, an accused manufacturer clearing a path to market, or litigation counsel preparing a claim or a defence, we scale to fit — a single claim chart, a multi-patent matter, or ongoing portfolio support. Send us the patent number and the accused device, and we will scope the work within one business day.

IP Landscape & Resources in Galway

Key intellectual-property authorities and venues relevant to Galway:

• Intellectual Property Office of Ireland (IPOI) — the national IP office (formerly the Patents Office) that grants Irish patents and registers Irish trademarks and designs, whose grants are enforced before the Irish High Court
• Courts Service of Ireland — the service for the Irish courts, including the High Court and its Commercial Court, which hears patent infringement and revocation actions under the Patents Act 1992 and its IP & Technology list
• European Patent Office (EPO) — the office that grants European patents which, once validated in Ireland, are enforced nationally before the Irish High Court because Ireland has not ratified the UPC Agreement
• Unified Patent Court (UPC) — the pan-European patent court; Ireland has signed but not yet ratified the UPC Agreement and is not a participating state, so there is no Irish UPC division and no unitary-patent effect in Ireland

Request a Patent Infringement Analysis in Galway

Explore related PerspireIP services: Patent Infringement Analysis · Prior Art Litigation Search · Patent Invalidation.

Frequently Asked Questions